Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...

In the dark days of the coronavirus pandemic, Moderna (NASDAQ: MRNA) was a ray of light in more ways than one. The healthcare ...

Moderna, Inc. (Nasdaq: MRNA), today announced its participation in the following upcoming investor conferences: ...

It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...

Have you assessed how the international operations of Moderna (MRNA) performed in the quarter ended December 2024? For this biotechnology company, possessing an expansive global footprint, parsing the ...

Moderna reported a wider loss than expected for the fourth quarter on Friday morning, and the drugmaker's sales forecast for ...

We recently published a list of 10 Firms Kick Off Shortened Trading Week With Impressive Gains. In this article, we are going ...

The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 11.8% in the morning session after it continued to build on the ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

The vaccine maker Moderna had no Valentine’s Day chocolates for investors when its fourth-quarter financial results came out ...